Search | Clinical Trials Finder

Conditions: Cardiac Transplant
Interventions: Daratumumab and hyaluronidase-fihj; Biological
Lead sponsor: Barry A. Boilson; Other
Eligibility: 18 Years to 80 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Psoriasis Guttate, Plaque Psoriasis
Interventions: Guselkumab; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Arthritis, Arthritis, Rheumatoid, Autoimmune Diseases
Interventions: Golimumab 50 mg SC, Golimumab 2 mg/kg IV, Methotrexate (MTX), Placebo SC, Placebo IV; Drug
Lead sponsor: Janssen Biotech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 433 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 89
States / cities: Birmingham, Alabama • Huntsville, Alabama • Tuscaloosa, Alabama + 86 more

Conditions: Psoriasis, Pregnancy, Psoriatic Arthritis, Crohn Disease
Interventions: Ustekinumab, Guselkumab; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: Female only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2031
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Bioavailability of ASP015K, Healthy Subjects, Pharmacokinetics of ASP015K, Food Effect of ASP015K
Interventions: ASP015K; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Adult Patients With Newly Diagnosed or Relapsed or Refractory Primary Central Nervous System Lymphoma (PCNSL), Or Relapsed or Refractory Secondary Central Nervous System Lymphoma (SCNSL)
Interventions: Ibrutinib, HD- Methotrexate (MTX), Rituximab + HD- Methotrexate (MTX), procarbazine; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2026
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Healthy Subjects
Interventions: Aprocitentan 25mg, Placebo; Drug
Lead sponsor: Idorsia Pharmaceuticals Ltd.; Industry
Eligibility: 20 Years to 45 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Anaheim, California

Conditions: Healthy Subjects, Pharmacokinetics of ASP015K
Interventions: ASP015K, verapamil; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Glendale, California

Conditions: Moderate to Severe Plaque Psoriasis
Interventions: No intervention; Other
Lead sponsor: Janssen Biotech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 9
States / cities: Phoenix, Arizona • Sacramento, California • Ann Arbor, Michigan + 6 more

Conditions: Lymphoma, B-Cell, Lymphoma, Non-Hodgkin, Leukemia, B-cell, Graft Vs Host Disease, Solid Tumor
Interventions: Ibrutinib; Drug
Lead sponsor: Pharmacyclics Switzerland GmbH; Industry
Eligibility: 18 Years and older
Enrollment: 297 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 34
States / cities: Burbank, California • Duarte, California • La Jolla, California + 27 more

Conditions: Arthritis, Rheumatoid
Interventions: Golimumab 2 mg/kg IV; Biological
Lead sponsor: Janssen Biotech, Inc.; Industry
Eligibility: 18 Years to 76 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 47
States / cities: Birmingham, Alabama • Huntsville, Alabama • Peoria, Arizona + 44 more

Conditions: Advanced Cancer
Interventions: Nivolumab, Daratumumab; Biological
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 5
States / cities: Long Beach, California • Aurora, Colorado • Tampa, Florida + 2 more

Conditions: Ulcerative Colitis
Interventions: Not listed
Lead sponsor: Janssen Biotech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 535 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 16
States / cities: Murrieta, California • Rialto, California • Ventura, California + 13 more

Conditions: Psoriasis
Interventions: Ustekinumab 45 mg, Ustekinumab 90 mg, Placebo; Drug
Lead sponsor: Janssen Biotech, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 478 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 40
States / cities: Birmingham, Alabama • Bakersfield, California • Irvine, California + 37 more

Conditions: Healthy Subjects, Pharmacokinetics of ASP015K
Interventions: ASP015K, Rosuvastatin; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Glendale, California

Conditions: Resistant Hypertension
Interventions: Aprocitentan 12.5 mg, Aprocitentan 25 mg, Placebo; Drug
Lead sponsor: Idorsia Pharmaceuticals Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 730 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 41
States / cities: Alexander City, Alabama • Inglewood, California • Lincoln, California + 37 more

Conditions: Arthritis, Rheumatoid
Interventions: peficitinib; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 611 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 20
States / cities: Birmingham, Alabama • La Jolla, California • Palm Desert, California + 17 more

Conditions: Relapsed or Refractory Mantle Cell Lymphoma
Interventions: Ibrutinib; Drug
Lead sponsor: Janssen Biotech, Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 44
States / cities: Phoenix, Arizona • Duarte, California • Los Angeles, California + 41 more

Conditions: Prostate Cancer, Prostatic Neoplasm
Interventions: abiraterone acetate in combination with prednisone; Drug
Lead sponsor: Janssen Biotech, Inc.; Industry
Eligibility: 18 Years to 99 Years · Male only
Enrollment: 131 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2024
U.S. locations: 45
States / cities: Homewood, Alabama • Huntsville, Alabama • Tucson, Arizona + 42 more

Conditions: Healthy Volunteers, Pharmacokinetics of ASP015K
Interventions: ASP015K, Placebo; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Glendale, California

Conditions: Crohn's Disease
Interventions: Infliximab, Placebo; Biological · Drug
Lead sponsor: Janssen Biotech, Inc.; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 297 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 62
States / cities: Birmingham, Alabama • La Jolla, California • Orange, California + 59 more

Conditions: Castration Resistant Prostate Cancer
Interventions: Abiraterone Acetate, Prednisone; Drug
Lead sponsor: Terence Friedlander, MD; Other
Eligibility: 18 Years and older · Male only
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 2
States / cities: San Francisco, California • Portland, Oregon

Conditions: T-cell Lymphoma, Relapsed and Refractory T-cell Lymphoma
Interventions: Ibrutinib; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 2
States / cities: New York, New York • Columbus, Ohio

Conditions: Crohn's Disease, Ulcerative Colitis, Indeterminate Colitis, Inflammatory Bowel Diseases
Interventions: Anti TNF therapy including infliximab, No Biologics; Biological · Drug
Lead sponsor: Janssen Biotech, Inc.; Industry
Eligibility: 1 Month to 17 Years
Enrollment: 4,970 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2038
U.S. locations: 58
States / cities: Mobile, Alabama • Phoenix, Arizona • Los Angeles, California + 55 more

Search by objective public record fields.

Daratumumab in HLA Desensitization Prior to Transplantation

Guselkumab Immunogenetics

Golimumab in Rheumatoid Arthritis Participants With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA)

Stelara and Tremfya Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy Project

A Study to Assess the Relative Bioavailability Between Two ASP015K Tablets and the Food Effect of a New Tablet in Healthy Adult Subjects

Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Patients With Newly Diagnosed or Refractory/Recurrent Primary Central Nervous System Lymphoma (PCNSL) and Refractory/Recurrent Secondary Central Nervous System Lymphoma (SCNSL)

A Study to Evaluate How Aprocitentan is Safe and How it is Absorbed and Broken Down in the Body of Japanese and Caucasian Subjects

A Study to Evaluate the Effect of Verapamil on the Pharmacokinetics of ASP015K in Healthy Adult Subjects

An Observational Study to Evaluate Patient-Reported Experiences of Living With Moderate-to-Severe Plaque Psoriasis

Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.

A Golimumab Phase 3b, Multicenter, Assessment of Intravenous Efficacy in Rheumatoid Arthritis Subjects Who Have Diminished Disease Control Despite Treatment With Infliximab (REMICADE®)

A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Pancreatic, Non-Small Cell Lung or Triple Negative Breast Cancers, That Have Advanced or Have Spread

An Observational Prospective Long-term Exposure Registry of Adult Patients With Moderate-to-Severe Ulcerative Colitis

A Study of Ustekinumab to Evaluate a "Subject-tailored" Maintenance Dosing Approach in Subjects With Moderate-to-Severe Plaque Psoriasis

Drug-Drug Interaction Study Evaluating Effects of ASP015K on Rosuvastatin

A Research Study to Show the Effect of Aprocitentan in the Treatment of Difficult to Control (Resistant) High Blood Pressure (Hypertension) and Find Out More About Its Safety

A Study to Evaluate the Long-term Safety and Efficacy of ASP015K in Subjects Previously Enrolled in a Phase 2 ASP015K Rheumatoid Arthritis Study

An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma

IMAAGEN: Impact of Abiraterone Acetate in Prostate-Specific Antigen

A Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP015K in Healthy Subjects

A Multicenter Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn's Disease (CD) Patients Undergoing Surgical Resection Who Are at an Increased Risk of Recurrence

A Phase II Study of Increased-Dose Abiraterone Acetate in Patients With Castration Resistant Prostate Cancer

Study of Ibrutinib in Relapsed and Refractory T-cell Lymphoma

A Multicenter, Prospective, Long-term, Observational Registry of Pediatric Patients With Inflammatory Bowel Disease